ERNEST HAWK to Adenoma
This is a "connection" page, showing publications ERNEST HAWK has written about Adenoma.
Connection Strength
2.022
-
Urinary PGE-M in colorectal cancer: predicting more than risk? Cancer Prev Res (Phila). 2014 Oct; 7(10):969-72.
Score: 0.329
-
Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev Res (Phila). 2013 Feb; 6(2):71-3.
Score: 0.296
-
Aspirin: still learning about the wonder drug. Gut. 2003 Nov; 52(11):1535-6.
Score: 0.156
-
Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol. 2018 10 01; 29(10):2061-2067.
Score: 0.110
-
Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol. 2018 08 01; 4(8):1085-1092.
Score: 0.109
-
The somatic mutation landscape of premalignant colorectal adenoma. Gut. 2018 07; 67(7):1299-1305.
Score: 0.100
-
Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prev Res (Phila). 2016 06; 9(6):417-27.
Score: 0.093
-
NSAID trials, sporadic adenomas, and conservative inferences. Gastroenterology. 1996 Feb; 110(2):654-5.
Score: 0.091
-
Adenoma detection in patients undergoing a comprehensive colonoscopy screening. Cancer Med. 2013 Jun; 2(3):391-402.
Score: 0.075
-
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011 Aug; 4(8):1172-80.
Score: 0.067
-
Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2010 May; 3(5):588-96.
Score: 0.061
-
The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010 Jun; 105(6):1437-43.
Score: 0.061
-
A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol. 2009 May; 7(5):568-74.
Score: 0.057
-
Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila). 2009 Apr; 2(4):310-21.
Score: 0.057
-
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009 Jun; 136(7):2127-2136.e1.
Score: 0.056
-
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):32-8.
Score: 0.054
-
Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):21-31.
Score: 0.053
-
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 05; 114(10):1028-35.
Score: 0.048
-
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31; 355(9):873-84.
Score: 0.048
-
Colorectal cancer screening for persons at average risk. J Natl Cancer Inst. 2002 Aug 07; 94(15):1126-33.
Score: 0.036
-
The future of colon cancer prevention. Ann N Y Acad Sci. 2001 Dec; 952:88-108.
Score: 0.034
-
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 2000 Apr 01; 60(7):1864-70.
Score: 0.030